UBS Group Lowers AdaptHealth (NASDAQ:AHCO) Price Target to $12.00

AdaptHealth (NASDAQ:AHCO) had its price target dropped by analysts at UBS Group from $13.00 to $12.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. UBS Group’s price target indicates a potential upside of 22.08% from the stock’s previous close.

Other analysts have also issued reports about the company. Royal Bank of Canada reissued an “outperform” rating and issued a $13.00 price objective on shares of AdaptHealth in a report on Monday, August 12th. Canaccord Genuity Group decreased their price target on shares of AdaptHealth from $14.00 to $13.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Robert W. Baird dropped their price objective on shares of AdaptHealth from $16.00 to $14.00 and set an “outperform” rating on the stock in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.36.

AdaptHealth Trading Down 3.4 %

AHCO opened at $9.83 on Wednesday. The firm’s 50 day moving average is $10.74 and its 200-day moving average is $10.44. The firm has a market capitalization of $1.32 billion, a P/E ratio of -1.88, a P/E/G ratio of 1.58 and a beta of 1.11. AdaptHealth has a 52-week low of $6.37 and a 52-week high of $11.90. The company has a quick ratio of 0.94, a current ratio of 1.15 and a debt-to-equity ratio of 1.38.

AdaptHealth (NASDAQ:AHCO) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.15 EPS for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.02). AdaptHealth had a positive return on equity of 9.58% and a negative net margin of 21.20%. The firm had revenue of $805.90 million during the quarter, compared to analyst estimates of $809.32 million. During the same quarter in the prior year, the firm earned $0.19 EPS. The business’s quarterly revenue was up .2% compared to the same quarter last year. Analysts expect that AdaptHealth will post 0.87 EPS for the current fiscal year.

Insider Buying and Selling at AdaptHealth

In other news, Director David Solomon Williams III sold 4,000 shares of the firm’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $11.26, for a total transaction of $45,040.00. Following the transaction, the director now directly owns 36,899 shares of the company’s stock, valued at approximately $415,482.74. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, COO Shaw Rietkerk sold 25,000 shares of the firm’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $11.24, for a total transaction of $281,000.00. Following the completion of the transaction, the chief operating officer now owns 212,611 shares in the company, valued at approximately $2,389,747.64. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director David Solomon Williams III sold 4,000 shares of the business’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $11.26, for a total transaction of $45,040.00. Following the completion of the sale, the director now owns 36,899 shares in the company, valued at $415,482.74. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.43% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in AHCO. Thrivent Financial for Lutherans grew its holdings in shares of AdaptHealth by 28.0% in the 3rd quarter. Thrivent Financial for Lutherans now owns 82,987 shares of the company’s stock worth $932,000 after acquiring an additional 18,136 shares during the last quarter. Mutual of America Capital Management LLC increased its stake in AdaptHealth by 23.8% in the 3rd quarter. Mutual of America Capital Management LLC now owns 15,893 shares of the company’s stock worth $178,000 after purchasing an additional 3,052 shares in the last quarter. Empowered Funds LLC raised its holdings in AdaptHealth by 5.4% during the 3rd quarter. Empowered Funds LLC now owns 570,900 shares of the company’s stock worth $6,411,000 after buying an additional 29,078 shares during the period. Royce & Associates LP lifted its stake in AdaptHealth by 13.5% during the third quarter. Royce & Associates LP now owns 777,405 shares of the company’s stock valued at $8,730,000 after buying an additional 92,740 shares in the last quarter. Finally, CIBC Asset Management Inc acquired a new position in shares of AdaptHealth in the third quarter worth about $122,000. Institutional investors and hedge funds own 82.67% of the company’s stock.

AdaptHealth Company Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.